Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease

Clinical Cardiology

Volumn 25, Issue 6, 2002, Pages 256-262

  Feldman, Arthur M ^a   McNamara, Dennis M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cilostazol; Cyclic adenosine monophosphate (AMP); Pentoxifylline; Peripheral arterial disease (PAD); Phosphodiesterase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENYLATE CYCLASE; AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXIMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; METOPROLOL; MILRINONE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; RECEPTOR PROTEIN; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR;

BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; INTERMITTENT CLAUDICATION; NEUTROPENIA; RASH; RESTENOSIS; REVIEW; SECOND MESSENGER; DRUG DESIGN; EVALUATION;

CARDIOVASCULAR DISEASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PHOSPHODIESTERASE INHIBITORS;

EID: 0035984729     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960250603     Document Type: Review

References (43)

1. Cardiotonic activity of amrinone - Win 40680 [5-amino-3,4′-bipyridine-6(1H)-one]
2. Influence of caffeine and other methylxanthines on mechanical properties of isolated mammalian heart muscle. Evidence for a dual mechanism of action
3. Direct vasodilator and positive inotropic actions of amrinone
4. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle
5. The Canadian American ticlopidine study (CATS) in thromboembolic stroke
6. Collaborative overview of randomised trials of antiplatelet therapy. 1. Preventions of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
8. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction
9. The prevalence of peripheral arterial disease in a defined population
10. Cilostazol has beneficial effects treating intermittent claudication: Results from a multi-center, randomized, prospective, double-blind trial
11. Medical treatment of peripheral arterial disease and claudication
12. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group
13. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
14. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
15. The effect of withdrawal of drugs treating intermittent claudication
16. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
17. Effect of cilostazol (Pletal™) on serum lipid levels in diabetic patients
18. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
19. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells
20. Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY4Y human neuroblastoma cells
21. Cilostazol, a phosphodiesterase inhibitor for the treatment of diabetic neuropathy
22. Effects of Pletal™ on incidence of sensory dysfunctions in diabetics
23. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication
24. Common variant in the AMPD1 gene predicts improved clinical outcome in patients with heart failure
25. Nitric oxide and postangioplasty restenosis: Pathological correlates and therapeutic potential
26. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
27. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
28. Comparison of cilostazol versus ticlopidine therapy after stent implantation
29. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation
30. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
31. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
32. Impact of cilostazol on intimal proliferation after directional coronary atherectomy
33. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
34. A dose-dependent increase in mortality with among patients with severe heart failure: Vesnarinone Trial Investigators
35. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure
36. Oral enoximone therapy in chronic heart failure: A placebo-controlled randomized trial. The Western Enoximone Study Group
37. Low-dose enoximone improves exercise capacity in chronic heart failure
38. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure
39. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: Results of a randomized study
40. The role of tumor necrosis factor in the pathophysiology of heart failure
41. Comparison of the effects of cilostzol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells
42. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction